前列腺癌放疗中计划与实施因素与疾病进展的关联:TROG 03.04 RADAR 试验结果
RADAR 试验纳入 2003–2007 年 813 例外照射放疗参与者,其中 709 例可分析,评估治疗计划与实施因素对局部复合进展(LCP)的影响。采用 Fine 和 Gray 竞争风险模型及 Kaplan-Meier 分析,发现使用 7 束及以上照射野和更严格剂量计算算法的患者 LCP 发生率显著更高。结论提示精确治疗需配合更高准确性以避免几何遗漏。
要点
- 7 束及以上照射野者 LCP 发生率显著高于 3 束者(亚风险比 3.056)。
- 使用更严格剂量计算算法者 LCP 发生率显著更高(亚风险比 1.686)。
- KM 分析显示相同组别 LCP 发生率更高,log-rank P 分别为 0.0005 和 0.0008。
核心结论
- 技术因素与前列腺癌放疗后局部复合进展相关,更精确的治疗需配合更高准确性以避免几何遗漏。
研究设计与样本
- RADAR 试验收集 2003–2007 年 813 例外照射放疗参与者的临床治疗因素数据,709 例纳入分析。
- 采用 Fine 和 Gray 竞争风险模型及 Kaplan-Meier 分析评估治疗计划与实施因素对局部复合进展的影响。
主要发现
- 使用 7 束及以上照射野者局部复合进展发生率显著更高,亚风险比 3.056(CI: 1.446-6.458,p < 0.0034)。
- 使用更严格剂量计算算法者局部复合进展发生率显著更高,亚风险比 1.686(CI: 1.334-2.132,p < 0.0001)。
- Kaplan-Meier 分析显示相同组别局部复合进展发生率更高,log-rank 检验 P 分别为 0.0005 和 0.0008。
临床怎么用
- 在前列腺癌放疗中,增加照射野数目或采用更严格剂量计算算法时需关注潜在几何遗漏风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: To evaluate the impact of treatment planning and delivery factors on treatment outcome as measured by post-treatment disease progression. MATERIALS AND METHODS: Accruing 813 external beam radiotherapy participants during 2003-2007, the RADAR trial collected a comprehensive range of clinical treatment factor data for each participant. Both the Fine and Gray competing risks modelling and the Kaplan-Meier (KM) analysis were undertaken to determine the impact of these factors on local-composite progression (LCP), with 709 participants available for analysis. RESULTS: Participants with treatments involving 7 or more beams experienced significantly higher incidence of LCP, with a sub-hazard ratio (relative to 3-beam participants) of 3.056 (CI: 1.446-6.458, p < 0.0034). Participants treated with a more rigorous dose calculation algorithm also displayed significantly higher incidence of LCP, with a sub-hazard ratio of 1.686 (CI: 1.334-2.132, p < 0.0001). The KM analysis resulted in the same groups showing a higher incidence of LCP, with log-rank test results of p = 0.0005 and p = 0.0008 respectively. CONCLUSIONS: The RADAR dataset has enabled a successful secondary analysis in which the impact of technical modifications has been assessed, challenging several established hypotheses. Increasingly precise treatments should be complemented with increasing accuracy to avoid potential geometric miss.
引用
- Marcello M, Ebert M, Haworth A, et al. Association between treatment planning and delivery factors and disease progression in prostate cancer radiotherapy: Results from the TROG 03.04 RADAR trial. Radiother Oncol. 2017. PMID: 29122360. doi:10.1016/j.radonc.2017.10.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。